Results 271 to 280 of about 170,520 (332)

CD59, Disulphide‐Locked Human C9 and Horse C9 Inhibit Human Membrane Attack Complex Assembly by Similar Mechanisms

open access: yesImmunology, Volume 176, Issue 3, Page 363-372, November 2025.
The membrane attack complex (MAC) is formed by the stepwise assembly of five proteins: C5b, C6, C7, C8 and C9. MAC plays a key role in driving inflammation in numerous diseases. This study compares the inhibitory mechanisms of MAC assembly by soluble CD59 (sCD59), a disulphide‐locked C9 mutant (C9lock) and horse C9 (HoC9).
Rebekah S. Cooke   +5 more
wiley   +1 more source

Quantitative analysis of human umbilical vein endothelial cell morphology and tubulogenesis

open access: yesJournal of Microscopy, Volume 300, Issue 2, Page 234-249, November 2025.
Abstract Primary human umbilical vein endothelial cells can grow as both a monolayer in culture and also as a capillary‐like network making them an ideal model system in order to study vascular remodelling. Image‐based analysis can allow assessment of cell morphology and motility but is dependent on accurate cell segmentation which requires high ...
Viviane Mignone   +6 more
wiley   +1 more source

Chemiexcitation in Ex Vivo Porcine Skin Model

open access: yesPigment Cell &Melanoma Research, Volume 38, Issue 6, November 2025.
Formation of triplet excited carbonyl by direct chemiexcitation in the fibroblasts of the dermis and in the melanocytes and keratinocytes of the epidermis in the porcine skin, followed by excitation energy transfer from triplet excited carbonyl to melanin via radiative and non‐radiative pathways by indirect chemiexcitation.
Pavel Pospíšil   +3 more
wiley   +1 more source

Pigment Epithelium‐Derived Factor (PEDF)‐Based Therapy Induced Photoreceptor Survival by Stabilizing Choroidal Neovessels in a VEGF Overexpression CNV Rat Model

open access: yesThe FASEB Journal, Volume 39, Issue 19, 15 October 2025.
Stabilizing choroidal neovessels offers a novel treatment‐option for pathological CNV. Pigment epithelium‐derived factor (PEDF), a multifunctional protein with vessel‐stabilizing properties, is a promising candidate for this approach. Its efficacy with and without bevacizumab was tested in a VEGF overexpression CNV rat model.
Alexander V. Tschulakow   +3 more
wiley   +1 more source

Real-World Outcomes of Antiangiogenic Therapy in Patients With Wet Age-Related Macular Degeneration. [PDF]

open access: yesCureus
Solano Pineda DL   +8 more
europepmc   +1 more source

The Comparative Effectiveness and Tolerability of Sphingosine‐1‐Phosphate Receptor Modulators in Patients With Multiple Sclerosis: A Network Meta‐Analysis of Randomized Controlled Trials

open access: yesAnnals of Clinical and Translational Neurology, Volume 12, Issue 10, Page 2002-2011, October 2025.
ABSTRACT Background Sphingosine‐1‐phosphate receptor modulators (S1PRM) are used to treat relapsing multiple sclerosis (MS). Each drug has a different S1PR‐subtype selectivity. They target the G‐protein coupled S1P receptors and exert significant immunomodulatory effects, such as preventing the formation of new CNS lesions and the reactivation of pre ...
Faizan Shahzad   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy